Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC857 (Utreloxastat) in ALS
NCT05349721Phase 2Terminated
- Sponsor
- PTC Therapeutics, Inc.
- Start
- May 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing PTC857 Arm with Placebo Arm (2 arms). Primary endpoint: Combined Assessment of Function (ALSFRS-R) and Survival Rank at 24 weeks. Started May 2022; status: terminated.
02
Drugs
utreloxastat
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05349721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349721.